sábado, 19 de agosto de 2017

Call for papers - Oncogenic Signaling of Tyrosine Kinase in Cancer

BioMed Central – The Open Access Publisher

Molecular Cancer invites you to submit to its new thematic series on Oncogenic Signaling of Tyrosine Kinase in Cancer: Challenges and Therapeutic Opportunities.
The series will cover all aspects related to expression, regulation and function of receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases and other kinases in oncogenic signaling in cancer cells. Other topics of interest relate to targeted therapies, tyrosine kinase inhibitors (TKI), genetic and epigenetic mechanisms of acquired resistance to TKI, clinical trials and pre-clinical studies.

Don’t miss out – deadline for submissions is 15 October 2017
The deadline for submissions is 15 October 2017. To submit your manuscript, please use Molecular Cancer's online submission system. Please use the 'Additional Information' tab to specify that you are submitting to this series.

Why publish with us?
High visibility – on average, articles are accessed over 80,000 times a month
Ranked in the top 14% in the Oncology category of Journal Citation Reports
Highly cited – articles place in top 1% in the Molecular Biology & Genetics field

Register to receive the latest articles, straight to your inbox.

Best wishes,

Christophe Nicot
Editor-in-Chief, Molecular Cancer
* The Impact Factor (IF) is just one measure used for evaluating the impact of research. For further information on the IF and alternative metrics used to measure the impact of research, please click here.

Follow BioMed Central:
For further information or enquiries please contact Customer Services at:info@biomedcentral.com.
BioMed Central Ltd
236 Gray's Inn Road, London, WC1X 8HB,
United Kingdom.

No hay comentarios:

Publicar un comentario